

Nikos Papakonstantinou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10659392/publications.pdf>

Version: 2024-02-01

21
papers

522
citations

759233

12
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

866
citing authors

#	ARTICLE	IF	CITATIONS
1	Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. <i>Haematologica</i> , 2011, 96, 1644-1652.	3.5	73
2	NF- κ B activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. <i>Seminars in Cancer Biology</i> , 2016, 39, 40-48.	9.6	60
3	Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. <i>Molecular Medicine</i> , 2012, 18, 1281-1291.	4.4	58
4	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , 2015, 125, 3580-3587.	1.4	49
5	Differential microRNA Profiles and Their Functional Implications in Different Immunogenetic Subsets of Chronic Lymphocytic Leukemia. <i>Molecular Medicine</i> , 2013, 19, 115-123.	4.4	46
6	A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. <i>Epigenetics</i> , 2013, 8, 1280-1288.	2.7	42
7	B Cell Anergy Modulated by TLR1/2 and the miR-17-1492 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4. <i>Journal of Immunology</i> , 2016, 196, 4410-4417.	0.8	30
8	The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 35946-35959.	1.8	29
9	EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia. <i>Epigenetics</i> , 2019, 14, 1125-1140.	2.7	24
10	Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 144, 2695-2706.	5.1	24
11	Heterogeneous Functional Effects of Concomitant B Cell Receptor and TLR Stimulation in Chronic Lymphocytic Leukemia with Mutated versus Unmutated Ig Genes. <i>Journal of Immunology</i> , 2014, 192, 4518-4524.	0.8	23
12	DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. <i>Clinical Epigenetics</i> , 2019, 11, 177.	4.1	15
13	Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis. , 2021, 9, e001889.		15
14	Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 1891-1896.	5.2	10
15	The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2419-2425.	1.3	9
16	Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. <i>Leukemia</i> , 2019, 33, 1030-1051.	7.2	4
17	Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 692-700.	3.5	4
18	Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 1876.	3.7	3

#	ARTICLE	IF	CITATIONS
19	Study of gene expressions' correlation structures in subgroups of Chronic Lymphocytic Leukemia Patients. Journal of Biomedical Informatics, 2019, 95, 103211.	4.3	2
20	A Structural Equation Modeling Approach of the Toll-Like Receptor Signaling Pathway in Chronic Lymphocytic Leukemia. , 2013, , .		1
21	The TÎp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia. Blood Advances, 2022, 6, 2646-2656.	5.2	1